Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Immunopathol Pharmacol ; 30(1): 25-43, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28124574

ABSTRACT

Recent studies have shown the therapeutic potential of curcumin in Alzheimer's disease (AD). In 2014, our lab found that curcumin reduced Aß40, Aß42 and Aß-derived diffusible ligands in the mouse hippocampus, and improved learning and memory. However, the mechanisms underlying this biological effect are only partially known. There is considerable evidence in brain metabolism studies indicating that AD might be a brain-specific type of diabetes with progressive impairment of glucose utilisation and insulin signalling. We hypothesised that curcumin might target both the glucose metabolism and insulin signalling pathways. In this study, we monitored brain glucose metabolism in living APPswe/PS1dE9 double transgenic mice using a micro-positron emission tomography (PET) technique. The study showed an improvement in cerebral glucose uptake in AD mice. For a more in-depth study, we used immunohistochemical (IHC) staining and western blot techniques to examine key factors in both glucose metabolism and brain insulin signalling pathways. The results showed that curcumin ameliorated the defective insulin signalling pathway by upregulating insulin-like growth factor (IGF)-1R, IRS-2, PI3K, p-PI3K, Akt and p-Akt protein expression while downregulating IR and IRS-1. Our study found that curcumin improved spatial learning and memory, at least in part, by increasing glucose metabolism and ameliorating the impaired insulin signalling pathways in the brain.


Subject(s)
Alzheimer Disease/metabolism , Brain/drug effects , Curcumin/pharmacology , Glucose/metabolism , Insulin/metabolism , Amyloid beta-Protein Precursor/genetics , Animals , Brain/metabolism , Insulin Receptor Substrate Proteins/metabolism , Memory/drug effects , Mice, Inbred C57BL , Mice, Transgenic , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Somatomedin/metabolism , Signal Transduction/drug effects , Spatial Learning/drug effects
2.
J Neurosci Res ; 92(2): 218-31, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24273069

ABSTRACT

Evidence suggests that curcumin, the phytochemical agent in the spice turmeric, might be a potential therapy for Alzheimer's disease (AD). Its antioxidant, anti-inflammatory properties have been investigated extensively. Studies have also shown that curcumin can reduce amyloid pathology in AD. The underlying mechanism, however, is complex and is still being explored. In this study, we used the APPswe/PS1dE9 double transgenic mice, an AD model, to investigate the effects and mechanisms of curcumin in the prevention and treatment of AD. The water maze test indicated that curcumin can improve spatial learning and memory ability in mice. Immunohistochemical staining and Western blot analysis were used to test major proteins in ß-amyloid aggregation, ß-amyloid production, and ß-amyloid clearance. Data showed that, 3 months after administration, curcumin treatment reduced Aß40 , Aß42 , and aggregation of Aß-derived diffusible ligands in the mouse hippocampal CA1 area; reduced the expression of the γ-secretase component presenilin-2; and increased the expression of ß-amyloid-degrading enzymes, including insulin-degrading enzymes and neprilysin. This evidence suggests that curcumin, as a potential AD therapeutic method, can reduce ß-amyloid pathological aggregation, possibly through mechanisms that prevent its production by inhibiting presenilin-2 and/or by accelerating its clearance by increasing degrading enzymes such as insulin-degrading enzyme and neprilysin.


Subject(s)
Alzheimer Disease/metabolism , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Curcumin/pharmacology , Maze Learning/drug effects , Memory/drug effects , Alzheimer Disease/pathology , Animals , Blotting, Western , Disease Models, Animal , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mice, Transgenic
3.
Restor Neurol Neurosci ; 31(5): 597-617, 2013.
Article in English | MEDLINE | ID: mdl-23760224

ABSTRACT

PURPOSE: Acute spinal cord injury (SCI) triggers multiple cellular and molecular pathways; therapy aimed at only one pathway is unlikely to succeed. Anecdotal reports indicate that a novel herbal formulation (JSK-Ji-Sui-Kang) may enhance recovery in humans with SCI. We investigated whether JSK's therapeutic effects could be verified in a well-established SCI model in rats. METHODS: Therapeutic effects of JSK were tested using a standard behavioral assessment, histological, immunochemical and microarray analysis. Phytochemical fingerprinting of JSK was performed using high performance liquid chromatography coupled with photodiode array detection and electrospray ionization-mass spectrometry. JSK or vehicle was gavaged to rats 24 hours after SCI and daily thereafter for 3 weeks. RESULTS: Locomotor function significantly improved (n = 12; p < 0.05), tissue damage was reduced (p < 0.01; n = 6) and more axons and myelin were observed in JSK-treated compared with vehicle control animals. JSK significantly enhanced expression of neuroglobin, vascular endothelial growth factor and growth-associated protein 43, and reduced the expression of caspase 3, cyclooxygenase-2, RhoA (p < 0.05; n = 6) and fibrinogen (p < 0.01; n = 6). RNA microarray indicated that JSK altered transcription of genes involved in ischemic and inflammatory/immune responses and apoptosis (p < 0.05; n = 3). CONCLUSIONS: JSK appears to target multiple biochemical and cellular pathways to enhance functional recovery and improve outcomes of SCI. The results provide a basis for further investigation of JSK's effects following SCI.


Subject(s)
Drugs, Chinese Herbal/therapeutic use , Plant Preparations/therapeutic use , Spinal Cord Injuries/drug therapy , Spinal Cord Injuries/pathology , Animals , Drugs, Chinese Herbal/chemistry , Female , Plant Preparations/chemistry , Rats , Rats, Wistar , Spinal Cord Injuries/metabolism , Treatment Outcome
4.
J Neurosci Res ; 91(2): 262-72, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23151946

ABSTRACT

After ischemic stroke, early thrombolytic therapy to reestablish tissue perfusion improves outcome but triggers a cascade of deleterious cellular and molecular events. Using a collaborative approach, our groups examined the effects of guanosine (Guo) in response to ischemic reperfusion injury in vitro and in vivo. In a transient middle cerebral artery occlusion (MCAO) in rats, Guo significantly reduced infarct volume in a dose-dependent manner when given systemically either immediately before or 30 min, but not 60 min, after the onset of the 5.5-hr reperfusion period. In a separate experiment, Guo significantly reduced infarct volume after 24 hr of reperfusion when administered 5 min before reperfusion. Western blot analysis did not reveal any significant changes either in endoplasmic reticulum (ER) stress proteins (GRP 78 and 94) or HSP 70 or in levels of m-calpain. In vitro oxygen and glucose deprivation (OGD) significantly increased production of both reactive oxygen species (ROS) and interleukin-8 (IL-8) in the primary astrocytes. Guo did not alter ROS or IL-8 production when given to the astrocytes before OGD. However, Guo when added to the cells prior to or 30 min after reperfusion significantly reduced IL-8 release but not ROS formation. Our study revealed a dose- and time-dependent protective effect of Guo on reperfusion injury in vitro and vivo. The mechanisms by which Guo exerts its effect are independent of unfolded proteins in ER or the level of intracellular calcium or ROS formation. However, the effect may be induced, at least partially, by inhibiting IL-8, a marker of reperfusion-triggered proinflammatory events.


Subject(s)
Brain Infarction/prevention & control , Guanosine/administration & dosage , Infarction, Middle Cerebral Artery/drug therapy , Neuroprotective Agents/administration & dosage , Reperfusion Injury/prevention & control , Analysis of Variance , Animals , Animals, Newborn , Astrocytes/drug effects , Astrocytes/metabolism , Brain Infarction/etiology , Cells, Cultured , Gene Expression Regulation/drug effects , Glucose/deficiency , Heat-Shock Proteins/metabolism , Hypoxia , Interleukin-8/metabolism , Male , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Reperfusion/adverse effects , Reperfusion Injury/complications , Time Factors
5.
Neural Regen Res ; 7(28): 2165-75, 2012 Oct 05.
Article in English | MEDLINE | ID: mdl-25538736

ABSTRACT

Previous studies have shown that transplanted enteric glia enhance axonal regeneration, reduce tissue damage, and promote functional recovery following spinal cord injury. However, the mechanisms by which enteric glia mediate these beneficial effects are unknown. Neurotrophic factors can promote neuronal differentiation, survival and neurite extension. We hypothesized that enteric glia may exert their protective effects against spinal cord injury partially through the secretion of neurotrophic factors. In the present study, we demonstrated that primary enteric glia cells release nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor over time with their concentrations reaching approximately 250, 100 and 50 pg/mL of culture medium respectively after 48 hours. The biological relevance of this secretion was assessed by incubating dissociated dorsal root ganglion neuronal cultures in enteric glia-conditioned medium with and/or without neutralizing antibodies to each of these proteins and evaluating the differences in neurite growth. We discovered that conditioned medium enhances neurite outgrowth in dorsal root ganglion neurons. Even though there was no detectable amount of neurotrophin-3 secretion using ELISA analysis, the neurite outgrowth effect can be attenuated by the antibody-mediated neutralization of each of the aforementioned neurotrophic factors. Therefore, enteric glia secrete nerve growth factor, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor and neurotrophin-3 into their surrounding environment in concentrations that can cause a biological effect.

6.
Brain Res ; 1407: 79-89, 2011 Aug 17.
Article in English | MEDLINE | ID: mdl-21774919

ABSTRACT

Previously we have found that extracellular guanosine (Guo) has neuroprotective properties in in vitro and in vivo. Moreover, extracellular Guo significantly increased in the ipsilateral hemisphere within 2h following focal stroke in rats, and remained elevated for one week. Therefore, we hypothesized that Guo could be a potential candidate for a non-toxic neuroprotective agent. In the present study, we examined the effects of Guo on rats following permanent middle cerebral artery occlusion (MCAO). We also determined whether Guo can precondition neurons by modulating endoplasmic reticulum (ER) stress proteins. As most therapies employ a combination treatment regimen, we optimized the neuroprotection by combining pre- and post-MCAO treatments with Guo, attempting to reduce both ischemic cell death and improve functional recovery. A combination of 4mg/kg Guo given 30min pre-stroke and 8mg/kg Guo given 3, 24 and 48h post-stroke exerted the most significant decrease in infarct volume and sustainable improvement in neurological function. Moreover, these effects are not attributable to Guo metabolites. Measurements taken 6h post-MCAO from animals pre-treated with Guo did not reveal any significant changes in ER stress proteins (GRP 78 and 94) or HSP 70, but did reveal significantly increased levels of m-calpain. Thus, our data indicate that there is a treatment regimen for Guo as a neuroprotectant following ischemic stroke. The mechanism by which Guo confers neuroprotection may involve an increase in m-calpain, possibly resulting from a mild increase in intracellular calcium. M-calpain may be involved in the preconditioning response to ischemia by upregulating endogenous pro-survival mechanisms in neurons.


Subject(s)
Brain Ischemia/drug therapy , Guanosine/therapeutic use , Stroke/drug therapy , Animals , Behavior, Animal/drug effects , Blotting, Western , Body Weight/drug effects , Brain Ischemia/complications , Brain Ischemia/pathology , Dose-Response Relationship, Drug , Eating/drug effects , Endoplasmic Reticulum/metabolism , Endoplasmic Reticulum Stress/physiology , Guanosine/administration & dosage , Heat-Shock Proteins/metabolism , Infarction, Middle Cerebral Artery/drug therapy , Infarction, Middle Cerebral Artery/pathology , Male , Membrane Glycoproteins/metabolism , Neurons/drug effects , Rats , Rats, Sprague-Dawley , Stroke/etiology , Stroke/pathology
7.
J Neurosci Res ; 87(3): 617-25, 2009 Feb 15.
Article in English | MEDLINE | ID: mdl-18816792

ABSTRACT

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) caused by an abnormal rate of apoptosis. Endogenous stem cells in the adult mammalian brain indicate an innate potential for regeneration and possible resource for neuroregeneration in PD. We previously showed that guanosine prevents apoptosis even when administered 48 hr after the toxin 1-methyl-4-phenylpyridinium (MPP(+)). Here, we induced parkinsonism in rats with a proteasome inhibitor. Guanosine treatment reduced apoptosis, increased tyrosine hydroxylase-positive dopaminergic neurons and expression of tyrosine hydroxylase in the SNc, increased cellular proliferation in the SNc and subventricular zone, and ameliorated symptoms. Proliferating cells in the subventricular zone were nestin-positive adult neural progenitor/stem cells. Fibroblast growth factor-2-expressing cells were also increased by guanosine. Thus, guanosine protected cells from apoptosis and stimulated "intrinsic" adult progenitor/stem cells to become dopaminergic neurons in rats with proteasome inhibitor-induced PD. The cellular/molecular mechanisms underlying these effects may open new avenues for development of novel therapeutics for PD.


Subject(s)
Apoptosis/drug effects , Guanosine/therapeutic use , Motor Activity/drug effects , Neurogenesis/drug effects , Parkinsonian Disorders/drug therapy , Animals , Bromodeoxyuridine , Dopamine/metabolism , Fibroblast Growth Factor 2/metabolism , Intermediate Filament Proteins/metabolism , Male , Nerve Tissue Proteins/metabolism , Nestin , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/therapeutic use , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/physiopathology , Rats , Rats, Sprague-Dawley , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Tyrosine 3-Monooxygenase/metabolism
8.
J Ind Microbiol Biotechnol ; 33(12): 1037-42, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16897082

ABSTRACT

In order to obtain an industrial strain with higher chitosanase yield, the wild strain Bacillus sp. S65 cells were mutated by a novel mutagen, nitrogen ion beam, with energy of 15 keV and dose ranging from 2.6 x 10(14 )to 5.2 x 10(15) ions/cm(2). One mutant, s65F5 with high yield of chitosanase was isolated. Results showed that the production of chitosanase of s65F5 was dramatically increased from 4.1 U/ml in s65 to 25 U/ml by ion beam implantation, while the fermentation time was shortened from 72 to 56 h, both of which greatly increased efficiency and reduced the cost of industrial production. Besides, the mutagenic effects of low-energy ion beam on survival rate showed characteristic down-up-down pattern, which was different from the traditional mutagens such as UV and gamma-ray and the possible mutation mechanism was discussed.


Subject(s)
Bacillus/enzymology , Bacillus/radiation effects , Genetic Engineering/methods , Glycoside Hydrolases/biosynthesis , Industrial Microbiology , Mutagenesis , Bacillus/genetics , Glycoside Hydrolases/genetics , Ions/chemistry , Mutation , Nitrogen Radioisotopes/chemistry
9.
J Agric Food Chem ; 54(12): 4208-14, 2006 Jun 14.
Article in English | MEDLINE | ID: mdl-16756348

ABSTRACT

For the production of oligosaccharides from chitosan, a chitosanase-producing bacterium, S65, was isolated from soil. On the basis of phylogenetic analysis of the 16S rDNA gene sequence and phenotypic analysis, S65 was identified as a Bacillus sp. strain. This bacterium constitutively produced chitosanase in a culture medium without chitosan as an inducer. S65 chitosanase was homogeneously purified by DEAE Sepharose fast flow anion exchange followed by Superdex 75 size exclusion, and the molecular weight was 45 kDa according to SDS-PAGE. Enzyme analysis showed that the optimum pH and temperature of S65 were 6.0 and 65 degrees C, respectively. Catalytic activity was stable from pH 5.5-6.5 at temperatures below 40 degrees C, and the pI of chitosanase was about 6.0 as determined by a test tube method. S65 chitosanase degraded carboxymethyl cellulose (CMC) at the degree of about 5.3% relative to the value of soluble chitosan, but it cannot hydrolyze colloidal chitin and crystalline cellulose. Gene encoding was cloned and sequenced. The deduced amino acid sequence of the S65 exhibited the highest homology to those of family 8 glycanase, suggesting that the enzyme belonged to family 8.


Subject(s)
Bacillus/enzymology , Cloning, Molecular , Glycoside Hydrolases/genetics , Glycoside Hydrolases/isolation & purification , Amino Acid Sequence , Bacillus/genetics , Bacillus/isolation & purification , Base Sequence , Catalysis , Cell Cycle Proteins , Glycoside Hydrolases/metabolism , Hydrogen-Ion Concentration , Isoelectric Point , Metals/pharmacology , Molecular Sequence Data , RNA, Ribosomal, 16S/genetics , Repressor Proteins , Saccharomyces cerevisiae Proteins , Soil Microbiology , Substrate Specificity , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...